Angiotensin II limits NO production by upregulating arginase through a p38 MAPK-ATF-2 pathway

Alia Shatanawi, Tahira Lemtalsi, Lin Yao, Chintan Patel, Ruth B Caldwell, Robert William Caldwell

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Enhanced vascular arginase activity can impair endothelium-dependent vasorelaxation by decreasing l-arginine availability to endothelial nitric oxide (NO) synthase, thereby reducing NO production and uncoupling NOS function. Elevated angiotensin II (Ang II) is a key component of endothelial dysfunction in many cardiovascular diseases and has been linked to elevated arginase activity. In this study we explored the signaling pathway leading to increased arginase expression/activity in response to Ang II in bovine aortic endothelial cells (BAEC). Our previous studies indicate involvement of p38 mitogen activated protein kinase (MAPK) in Ang II-induced arginase upregulation and reduced NO production. In this study, we further investigated the Ang II-transcriptional regulation of arginase 1 in endothelial cells. Our results indicate the involvement of ATF-2 transcription factor of the AP1 family in arginase 1 upregulation and in limiting NO production. Using small interfering RNA (siRNA) targeting ATF-2, we showed that this transcription factor is required for Ang II-induced arginase 1 gene upregulation and increased arginase 1 expression and activity, leading to reduced NO production. Electrophoretic mobility shift assay and chromatin immunoprecipitation assay further confirmed the involvement of ATF-2. Moreover, our data indicate that p38 MAPK phosphorylates ATF-2 in response to Ang II. Collectively, our results indicate that Ang II increases endothelial arginase activity/expression through a p38 MAPK/ATF-2 pathway leading to reduced endothelial NO production. These signaling steps might be therapeutic targets for preventing vascular endothelial dysfunction associated with elevated arginase activity/expression.

Original languageEnglish (US)
Pages (from-to)106-114
Number of pages9
JournalEuropean Journal of Pharmacology
Volume746
DOIs
StatePublished - Jan 5 2015

Fingerprint

Arginase
Mitogen-Activated Protein Kinase 1
p38 Mitogen-Activated Protein Kinases
Angiotensin II
Nitric Oxide
Up-Regulation
Blood Vessels
Endothelial Cells
Activating Transcription Factors
Nitric Oxide Synthase Type III
Chromatin Immunoprecipitation
Electrophoretic Mobility Shift Assay
Vasodilation
Small Interfering RNA
Endothelium
Arginine
Transcription Factors
Cardiovascular Diseases

Keywords

  • ATF-2
  • Angiotensin II
  • Arginase
  • Nitric oxide (NO)
  • Transcription factors
  • p38 MAPK

ASJC Scopus subject areas

  • Pharmacology

Cite this

Angiotensin II limits NO production by upregulating arginase through a p38 MAPK-ATF-2 pathway. / Shatanawi, Alia; Lemtalsi, Tahira; Yao, Lin; Patel, Chintan; Caldwell, Ruth B; Caldwell, Robert William.

In: European Journal of Pharmacology, Vol. 746, 05.01.2015, p. 106-114.

Research output: Contribution to journalArticle

@article{86805cd215ac4006a17498ecdaa5b4b7,
title = "Angiotensin II limits NO production by upregulating arginase through a p38 MAPK-ATF-2 pathway",
abstract = "Enhanced vascular arginase activity can impair endothelium-dependent vasorelaxation by decreasing l-arginine availability to endothelial nitric oxide (NO) synthase, thereby reducing NO production and uncoupling NOS function. Elevated angiotensin II (Ang II) is a key component of endothelial dysfunction in many cardiovascular diseases and has been linked to elevated arginase activity. In this study we explored the signaling pathway leading to increased arginase expression/activity in response to Ang II in bovine aortic endothelial cells (BAEC). Our previous studies indicate involvement of p38 mitogen activated protein kinase (MAPK) in Ang II-induced arginase upregulation and reduced NO production. In this study, we further investigated the Ang II-transcriptional regulation of arginase 1 in endothelial cells. Our results indicate the involvement of ATF-2 transcription factor of the AP1 family in arginase 1 upregulation and in limiting NO production. Using small interfering RNA (siRNA) targeting ATF-2, we showed that this transcription factor is required for Ang II-induced arginase 1 gene upregulation and increased arginase 1 expression and activity, leading to reduced NO production. Electrophoretic mobility shift assay and chromatin immunoprecipitation assay further confirmed the involvement of ATF-2. Moreover, our data indicate that p38 MAPK phosphorylates ATF-2 in response to Ang II. Collectively, our results indicate that Ang II increases endothelial arginase activity/expression through a p38 MAPK/ATF-2 pathway leading to reduced endothelial NO production. These signaling steps might be therapeutic targets for preventing vascular endothelial dysfunction associated with elevated arginase activity/expression.",
keywords = "ATF-2, Angiotensin II, Arginase, Nitric oxide (NO), Transcription factors, p38 MAPK",
author = "Alia Shatanawi and Tahira Lemtalsi and Lin Yao and Chintan Patel and Caldwell, {Ruth B} and Caldwell, {Robert William}",
year = "2015",
month = "1",
day = "5",
doi = "10.1016/j.ejphar.2014.10.042",
language = "English (US)",
volume = "746",
pages = "106--114",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - Angiotensin II limits NO production by upregulating arginase through a p38 MAPK-ATF-2 pathway

AU - Shatanawi, Alia

AU - Lemtalsi, Tahira

AU - Yao, Lin

AU - Patel, Chintan

AU - Caldwell, Ruth B

AU - Caldwell, Robert William

PY - 2015/1/5

Y1 - 2015/1/5

N2 - Enhanced vascular arginase activity can impair endothelium-dependent vasorelaxation by decreasing l-arginine availability to endothelial nitric oxide (NO) synthase, thereby reducing NO production and uncoupling NOS function. Elevated angiotensin II (Ang II) is a key component of endothelial dysfunction in many cardiovascular diseases and has been linked to elevated arginase activity. In this study we explored the signaling pathway leading to increased arginase expression/activity in response to Ang II in bovine aortic endothelial cells (BAEC). Our previous studies indicate involvement of p38 mitogen activated protein kinase (MAPK) in Ang II-induced arginase upregulation and reduced NO production. In this study, we further investigated the Ang II-transcriptional regulation of arginase 1 in endothelial cells. Our results indicate the involvement of ATF-2 transcription factor of the AP1 family in arginase 1 upregulation and in limiting NO production. Using small interfering RNA (siRNA) targeting ATF-2, we showed that this transcription factor is required for Ang II-induced arginase 1 gene upregulation and increased arginase 1 expression and activity, leading to reduced NO production. Electrophoretic mobility shift assay and chromatin immunoprecipitation assay further confirmed the involvement of ATF-2. Moreover, our data indicate that p38 MAPK phosphorylates ATF-2 in response to Ang II. Collectively, our results indicate that Ang II increases endothelial arginase activity/expression through a p38 MAPK/ATF-2 pathway leading to reduced endothelial NO production. These signaling steps might be therapeutic targets for preventing vascular endothelial dysfunction associated with elevated arginase activity/expression.

AB - Enhanced vascular arginase activity can impair endothelium-dependent vasorelaxation by decreasing l-arginine availability to endothelial nitric oxide (NO) synthase, thereby reducing NO production and uncoupling NOS function. Elevated angiotensin II (Ang II) is a key component of endothelial dysfunction in many cardiovascular diseases and has been linked to elevated arginase activity. In this study we explored the signaling pathway leading to increased arginase expression/activity in response to Ang II in bovine aortic endothelial cells (BAEC). Our previous studies indicate involvement of p38 mitogen activated protein kinase (MAPK) in Ang II-induced arginase upregulation and reduced NO production. In this study, we further investigated the Ang II-transcriptional regulation of arginase 1 in endothelial cells. Our results indicate the involvement of ATF-2 transcription factor of the AP1 family in arginase 1 upregulation and in limiting NO production. Using small interfering RNA (siRNA) targeting ATF-2, we showed that this transcription factor is required for Ang II-induced arginase 1 gene upregulation and increased arginase 1 expression and activity, leading to reduced NO production. Electrophoretic mobility shift assay and chromatin immunoprecipitation assay further confirmed the involvement of ATF-2. Moreover, our data indicate that p38 MAPK phosphorylates ATF-2 in response to Ang II. Collectively, our results indicate that Ang II increases endothelial arginase activity/expression through a p38 MAPK/ATF-2 pathway leading to reduced endothelial NO production. These signaling steps might be therapeutic targets for preventing vascular endothelial dysfunction associated with elevated arginase activity/expression.

KW - ATF-2

KW - Angiotensin II

KW - Arginase

KW - Nitric oxide (NO)

KW - Transcription factors

KW - p38 MAPK

UR - http://www.scopus.com/inward/record.url?scp=84949116884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949116884&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2014.10.042

DO - 10.1016/j.ejphar.2014.10.042

M3 - Article

C2 - 25446432

AN - SCOPUS:84949116884

VL - 746

SP - 106

EP - 114

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -